TNNI3K polyclonal, anti-human, mouse, rat
€305.00
In stock
SKU
BS61266
Background:
TNNI3K (TNNI3-interacting kinase), also known as CARK (Cardiac ankyrin repeat kinase), is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.
Alternative Name:
Serine/threonine-protein kinase TNNI3K (EC:2.7.11.1), Cardiac ankyrin repeat kinase, Cardiac troponin I-interacting kinase, TNNI3-interacting kinase, TNNI3K, CARK
Application Dilution: WB: 1:500~1:1000
Specificity: TNNI3K polyclonal antibody detects endogenous levels of TNNI3K protein.
Immunogen:
A synthetic peptide corresponding to residues in Human TNNI3K.
MW: ~ 78 kDa
Swis Prot.: Q59H18
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.3.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
TNNI3K (TNNI3-interacting kinase), also known as CARK (Cardiac ankyrin repeat kinase), is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.
Alternative Name:
Serine/threonine-protein kinase TNNI3K (EC:2.7.11.1), Cardiac ankyrin repeat kinase, Cardiac troponin I-interacting kinase, TNNI3-interacting kinase, TNNI3K, CARK
Application Dilution: WB: 1:500~1:1000
Specificity: TNNI3K polyclonal antibody detects endogenous levels of TNNI3K protein.
Immunogen:
A synthetic peptide corresponding to residues in Human TNNI3K.
MW: ~ 78 kDa
Swis Prot.: Q59H18
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.3.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review